288 related articles for article (PubMed ID: 33631016)
61. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.
Kilburn LB; Kocak M; Baxter P; Poussaint TY; Paulino AC; McIntyre C; Lemenuel-Diot A; Lopez-Diaz C; Kun L; Chintagumpala M; Su JM; Broniscer A; Baker JN; Hwang EI; Fouladi M; Boyett JM; Blaney SM
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29090526
[TBL] [Abstract][Full Text] [Related]
62. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
63. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.
Balcer LJ; Liu GT; Heller G; Bilaniuk L; Volpe NJ; Galetta SL; Molloy PT; Phillips PC; Janss AJ; Vaughn S; Maguire MG
Am J Ophthalmol; 2001 Apr; 131(4):442-5. PubMed ID: 11292406
[TBL] [Abstract][Full Text] [Related]
64. Radiation therapy of optico-hypothalamic gliomas (OHG)--radiographic response, vision and late toxicity.
Grabenbauer GG; Schuchardt U; Buchfelder M; Rödel CM; Gusek G; Marx M; Doerr HG; Fahlbusch R; Huk WJ; Wenzel D; Sauer R
Radiother Oncol; 2000 Mar; 54(3):239-45. PubMed ID: 10738082
[TBL] [Abstract][Full Text] [Related]
65. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA
Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534
[TBL] [Abstract][Full Text] [Related]
66. Optic pathway gliomas in children with and without neurofibromatosis 1.
Czyzyk E; Jóźwiak S; Roszkowski M; Schwartz RA
J Child Neurol; 2003 Jul; 18(7):471-8. PubMed ID: 12940652
[TBL] [Abstract][Full Text] [Related]
67. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
68. Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.
Dotto PF; Berezovsky A; Cappellano AM; da Silva NS; Sacai PY; Silva FAB; Fernandes AG; Rocha DM; Salomão SR
Doc Ophthalmol; 2018 Jun; 136(3):177-189. PubMed ID: 29766345
[TBL] [Abstract][Full Text] [Related]
69. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
[TBL] [Abstract][Full Text] [Related]
70. Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma.
Brossier NM; Thondapu S; Cobb OM; Dahiya S; Gutmann DH
Neuro Oncol; 2021 Apr; 23(4):625-637. PubMed ID: 33080011
[TBL] [Abstract][Full Text] [Related]
71. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
72. Radiation Therapy for Optic Pathway and Hypothalamic Low-Grade Gliomas in Children.
Tsang DS; Murphy ES; Merchant TE
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):642-651. PubMed ID: 29280458
[TBL] [Abstract][Full Text] [Related]
73. Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.
Strowd RE; Rodriguez FJ; McLendon RE; Vredenburgh JJ; Chance AB; Jallo G; Olivi A; Ahn ES; Blakeley JO
Am J Med Genet A; 2016 Jun; 170(6):1455-61. PubMed ID: 26992069
[TBL] [Abstract][Full Text] [Related]
74. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
[TBL] [Abstract][Full Text] [Related]
75. Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study.
Heidary G; Fisher MJ; Liu GT; Ferner RE; Gutmann DH; Listernick RH; Kapur K; Loguidice M; Ardern-Holmes SL; Avery RA; Hammond C; Hoffman RO; Hummel TR; Kuo A; Reginald A; Ullrich NJ
J AAPOS; 2020 Dec; 24(6):349.e1-349.e5. PubMed ID: 33221469
[TBL] [Abstract][Full Text] [Related]
76. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Holkova B; Zingone A; Kmieciak M; Bose P; Badros AZ; Voorhees PM; Baz R; Korde N; Lin HY; Chen JQ; Herrmann M; Xi L; Raffeld M; Zhao X; Wan W; Tombes MB; Shrader E; Weir-Wiggins C; Sankala H; Hogan KT; Doyle A; Annunziata CM; Wellons M; Roberts JD; Sullivan D; Landgren O; Grant S
Clin Cancer Res; 2016 Mar; 22(5):1067-75. PubMed ID: 26446942
[TBL] [Abstract][Full Text] [Related]
77. Comparison of multi-shot and single shot echo-planar diffusion tensor techniques for the optic pathway in patients with neurofibromatosis type 1.
Ho CY; Deardorff R; Kralik SF; West JD; Wu YC; Shih CS
Neuroradiology; 2019 Apr; 61(4):431-441. PubMed ID: 30684113
[TBL] [Abstract][Full Text] [Related]
78. The role of early intra-operative MRI in partial resection of optic pathway/hypothalamic gliomas in children.
Millward CP; Perez Da Rosa S; Avula S; Ellenbogen JR; Spiteri M; Lewis E; Didi M; Mallucci C
Childs Nerv Syst; 2015 Nov; 31(11):2055-62. PubMed ID: 26216059
[TBL] [Abstract][Full Text] [Related]
79. Management of optic-hypothalamic gliomas in children: still a challenging problem.
Massimi L; Tufo T; Di Rocco C
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1591-610. PubMed ID: 18020927
[TBL] [Abstract][Full Text] [Related]
80. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas.
Bartels U; Hawkins C; Jing M; Ho M; Dirks P; Rutka J; Stephens D; Bouffet E
J Neurosurg; 2006 May; 104(5 Suppl):314-20. PubMed ID: 16848088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
